Lidocaína Adrenalina Labesfal

Lidocaine hydrochloride and epinephrine bitartrate, the active ingredient in Lidocaína Adrenalina Labesfal, is a local anesthetic with vasoconstrictor presented as a sterile solution for subcutaneous administration. It is used to achieve rapid, reversible loss of sensation in minor surgical, dental and dermatologic procedures for adult patients.

GNH USA supplies Lidocaína Adrenalina Labesfal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including procurement teams in transplant and oncology centres.

Lidocaína Adrenalina Labesfal, a combination local anesthetic with vasoconstrictor, is indicated for procedures requiring soft‑tissue anesthesia.

- Minor surgical procedures: provides localized numbness to facilitate incision, excision and suturing. - Dental procedures: enables painless soft‑tissue work such as extractions, root canal access and periodontal surgery. - Dermatologic or cosmetic interventions: allows infiltration anesthesia for skin lesion removal, laser therapy or minor cosmetic surgery.

Adverse reactions to Lidocaína Adrenalina Labesfal may vary in frequency and severity.

Common Side Effects: - Tingling or numbness at the injection site - Mild swelling or erythema - Transient dizziness - Headache - Nausea - Elevated heart rate (palpitations)

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmias - Seizures - Methemoglobinemia - Persistent hypotension - Tissue necrosis at the injection site

When using Lidocaína Adrenalina Labesfal, clinicians should observe several safety measures.

- Assess patient allergy: verify no known hypersensitivity to lidocaine, epinephrine or amide anesthetics. - Review cardiovascular status: avoid in patients with uncontrolled hypertension, arrhythmias, or recent myocardial infarction. - Limit dosage: adhere to the recommended maximum dose based on patient weight and injection site. - Use caution with MAO inhibitors or tricyclic antidepressants: these may increase systemic toxicity. - Monitor for signs of systemic toxicity: watch for CNS or cardiovascular symptoms. - Store at room temperature: keep in the original container, protect from light and moisture.

Lidocaína Adrenalina Labesfal can interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - MAO inhibitors: increased risk of hypertensive crisis with epinephrine. - β‑blockers: may potentiate epinephrine‑induced tachycardia. - Class I antiarrhythmics (e.g., quinidine): can exacerbate lidocaine toxicity. - Tricyclic antidepressants: raise lidocaine plasma levels. - Non‑selective α‑adrenergic antagonists: reduce vasoconstrictive effect of epinephrine.

Moderate Interactions (Monitor Closely): - Antihistamines: may mask early signs of allergic reaction. - Diuretics: alter plasma volume affecting drug distribution. - CYP3A4 inhibitors (e.g., erythromycin): modestly increase lidocaine levels. - Sympathomimetic drugs (e.g., phenylephrine): additive vasoconstriction. - Alcohol: may enhance central nervous system depression.